Blog | Page 2 of 37 | Oncotarget

Oncotarget News

METTL3 Drives Oral Cancer by Blocking Tumor-Suppressing Gene

May 9, 2025

we report that METTL3, an oncogene regulates the expression of SMAD4, a tumor-suppressor via miR-146a-5p, thus unveiling a novel regulatory axis of METTL3/miR-146a-5p/SMAD4 in OSCC, which can potentially... read more

Oncotarget

Oncotarget Participation at SSP 2025 Annual Meeting

May 5, 2025

Oncotarget will be represented by Impact Journals as an exhibitor at the Society for Scholarly Publishing (SSP) 47th Annual Meeting, taking place from May 28–30, 2025, in Baltimore, Maryland.... read more

Oncotarget

Early Immune Evasion Found in HPV-Related Pre-Cancer Lesions of the Anogenital Region

April 28, 2025

This study demonstrated that the inflammatory response in a subset of anal, penile, and vulvar HSILs was associated with PD-L1 and FOXP3 expression."BUFFALO, NY - April 28, 2025 – A new... read more

Oncotarget

Gene Variant Linked to Benign Prostate Hyperplasia Risk in Lebanese Men

April 15, 2025

Our results indicate a strong association between certain genotypes of the SNP -765 G>C of the PTGS2 gene and BPH."BUFFALO, NY - April 15, 2025 – A new research... read more

Oncotarget

Protein GSK3β Offers New Angle on Overcoming Melanoma Drug Resistance

April 11, 2025

Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression.”BUFFALO, NY -... read more

Oncotarget

AI That Measures Its Own Uncertainty Could Improve Liver Cancer Detection

April 8, 2025

These advancements, by providing more reliable and efficient diagnostic tools, may significantly impact clinical practice by addressing the ever-growing clinical demand and work pressure, while maintaining interpretability and clinical relevance.”... read more

Oncotarget

Triple Therapy Slows Glioblastoma Growth and Extends Survival in Preclinical Study

April 4, 2025

Our findings demonstrate for the first time that IRT therapy combining ONC201 or ONC206 with RT and TMZ may be a safe and effective therapeutic strategy for GBM.”BUFFALO, NY -... read more

Oncotarget

NSD2 Gene Drives Cancer Cell Identity in Multiple Myeloma

April 2, 2025

Our findings suggest a role for NSD2 in maintaining MM cell identity, with potential implications for future therapeutic strategies based on targeting of NSD2.”BUFFALO, NY - April 2, 2025 – A... read more